Jiang Linkui's Personality Achievement

Establish a new management mechanism to adapt to the development of market economy

First, increase foreign investment and expand industrial space. Since 200 1, it has successively acquired Suihua Mingshui Pharmaceutical Co., Ltd., Suihua Pharmaceutical Co., Ltd., Harbin North Pharmaceutical Co., Ltd., Sanjing Ruipu Co., Ltd. and Heihe Pharmaceutical Co., Ltd. Through a series of capital operations, they not only found the production space of superior products for the third pharmaceutical factory, but also established a diversified legal entity, completed the transformation from factory system to company system, and quickly became the pillar enterprise of the group.

In 2003, Sanjing Pharmaceutical Company achieved sales income of 654.38+0.24 billion yuan, up 30% year-on-year.

Second, with the help of the capital market, expand the investment and financing channels of enterprises and promote the expansion of equity. At the end of 2003, it formally signed the Equity Transfer Agreement with Harbin Building Materials Industry (Group) Co., Ltd., and acquired its 46.07% equity in Harbin Swan Industrial Co., Ltd. (a listed company) twice, and Chengfeng obtained the relative controlling stake in Swan Co., Ltd. On September 30, 2004, with the approval of Shanghai Stock Exchange, Swan (600829) was officially renamed as "Harbin Harbin Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd." (the stock is abbreviated as Sanjing Pharmaceutical), which was successfully realized.

The third is to integrate market resources, aim at high technology and implement strategic adjustment of product structure. Since 200 1, the scale of technological transformation of Harbin pharmaceutical group has been expanding, with a total investment of more than 65,438 billion yuan, and there are only 9 technological transformation projects listed as national key projects. Harbin Pharmaceutical Group eliminated 15 varieties with small scale and low efficiency. By the end of 2003, the new benefits of technological transformation accounted for more than 60% of the new benefits of the whole group's industry and became a new economic growth point. In the list of the most valuable brands in China in 2003 released a few days ago, the brand value of "Sanjing Pharmaceutical" of Harbin Pharmaceutical Group was assessed as 3.33 billion yuan. In addition, "Sanjing Pharmaceutical" was also recognized as "China famous trademark".